Vis enkel innførsel

dc.contributor.authorØvrehus, Marius Altern
dc.contributor.authorZürbig, Petra
dc.contributor.authorVikse, Bjørn Egil
dc.contributor.authorHallan, Stein
dc.date.accessioned2015-11-10T09:57:41Z
dc.date.accessioned2015-11-24T11:29:29Z
dc.date.available2015-11-10T09:57:41Z
dc.date.available2015-11-24T11:29:29Z
dc.date.issued2015
dc.identifier.citationClinical Proteomics 2015, 12(1)nb_NO
dc.identifier.issn1559-0275
dc.identifier.urihttp://hdl.handle.net/11250/2365414
dc.description.abstractBackground: The contrast between a high prevalence of chronic kidney disease (CKD) and the low incidence of end-stage renal disease highlights the need for new biomarkers of progression beyond albuminuria testing. Urinary proteomics is a promising method, but more studies focusing on progression rate and patients with hypertensive nephropathy are needed. Results: We analyzed urine samples with capillary electrophoresis coupled to a mass-spectrometer from 18 well characterized patients with CKD stage 4–5 (of whom six with hypertensive nephropathy) and 17 healthy controls. Classification scores based on a previously developed panel of 273 urinary peptides were calculated and compared to urine albumin dipstick results. Urinary proteomics classified CKD with a sensitivity of 0.95 and specificity of 1.00. Overall diagnostic accuracy (area under ROC curve) was 0.98, which was better than for albuminuria (0.85, p = 0.02). Results for hypertensive nephropathy were similar to other CKD diagnoses. Adding the proteomic score to an albuminuria model improved detection of rapid kidney function decline (>4 ml/min/1.73 m2 per year) substantially: area under ROC curve increased from 0.762 to 0.909 (p = 0.042), and 38% of rapid progressors were correctly reclassified to a higher risk and 55% of slow progressors were correctly reclassified to a lower risk category. Reduced excretion of collagen types I–III, uromodulin, and other indicators of interstitial inflammation, fibrosis and tubular dysfunction were associated with CKD diagnosis and rapid progression. Patients with hypertensive nephropathy displayed the same findings as other types of CKD. Conclusions: Urinary proteomic analyses had a high diagnostic accuracy for CKD, including hypertensive nephropathy, and strongly improved identification of patients with rapid kidney function decline beyond albuminuria testing. Keywords: Chronic kidney disease, Hypertensive nephropathy, Urine, Albuminuria, Proteomics, Disease progressionnb_NO
dc.language.isoengnb_NO
dc.publisherBioMed Centralnb_NO
dc.titleUrinary proteomics in chronic kidney disease: diagnosis and risk of progression beyond albuminurianb_NO
dc.typeJournal articlenb_NO
dc.typePeer revieweden_GB
dc.date.updated2015-11-10T09:57:41Z
dc.source.volume12nb_NO
dc.source.journalClinical Proteomicsnb_NO
dc.source.issue1nb_NO
dc.identifier.doi10.1186/s12014-015-9092-7
dc.identifier.cristin1264877
dc.description.localcode© 2015 Øvrehus et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.nb_NO


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel